| Globe & Mail (Toronto, Canada) 2006 Leonard Zehr |
| Title | Subject | Authors |
|---|
| Angiotech to buy top medical devices company.(Angiotech Pharmaceuticals Inc.)(American Medical Instruments Holdings Inc.) | News, opinion and commentary | Leonard Zehr |
| Battle lines being drawn in U.S. cholesterol drug wars.(Pfizer and other pharmaceutical companies) | News, opinion and commentary | Leonard Zehr |
| Biotech deals could surpass $1.5-billion.(acquisition deals of Canadian biotech industry ) | News, opinion and commentary | Leonard Zehr |
| Biotech firm prepares for pandemic.(Microbix Biosystems Inc., avian flu)(Interview) | News, opinion and commentary | Leonard Zehr |
| Biovail hammered by patent ruling. | News, opinion and commentary | Leonard Zehr |
| Biovail making strategic overhaul.(business restructuring) | News, opinion and commentary | Leonard Zehr |
| Cash-heavy Biovail on the prowl for deals.(business growth) | News, opinion and commentary | Leonard Zehr |
| Cholesterol drug companies under the gun as patents expire.(cholesterol drug patents) | News, opinion and commentary | Leonard Zehr |
| Dissident shareholders launch Wex proxy battle.(Wex Pharmaceuticals Inc.) | News, opinion and commentary | Leonard Zehr |
| Jamieson eyes $175-million trust IPO.(Jamieson Laboratories Ltd.)(initial public offerings) | News, opinion and commentary | Leonard Zehr, Sinclair Stewart |
| Labopharm feels market pain from delayed approval of new drug. | News, opinion and commentary | Leonard Zehr |
| Melnyk's new title reflects reduced role.(Eugene Melnyk) | News, opinion and commentary | Leonard Zehr |
| Neuromed strikes major Merck deal.(Neuromed Pharmaceuticals Ltd., Merck and Company Inc.) | News, opinion and commentary | Leonard Zehr |
| N.Y. investors reject AnorMed board proposal.(New York) | News, opinion and commentary | Leonard Zehr |
| OccuLogix shares plummet 65%. | News, opinion and commentary | Leonard Zehr |
| QLT plans $104-million stock buyback.(2006 profit downfall) | News, opinion and commentary | Leonard Zehr |
| Sale of Patheon one step closer after company hires advisers. | News, opinion and commentary | Leonard Zehr |
| Three late-stage products rev up interest in Cipher.(new drugs from Cipher Pharmaceuticals Inc.) | News, opinion and commentary | Leonard Zehr |
| Water treatment play Zenon goes to GE.(General Electric Co. acquires Zenon Environmental Inc.) | News, opinion and commentary | Leonard Zehr |
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
